Evaluation of prosthetic functionality
Prosthetic valve dysfunction occurred in 18 patients (22.5%), without a
difference between patients treated with biological vs. mechanical valve
prostheses (p = 0.96). The main complications were anterior paravalvular
leak with a frequency of (15%).
The proportion of prosthetic valve dysfunction at 12 years after AVR is
75% for patients with bioprostheses (95% CI = 0.49-0.93) and 50% for
mechanical prostheses (95% CI = 0.19 -0.88). The Wilcoxon test did not
show statistical significance between the percentages of prosthetic
dysfunction over time (p = 0.45). The restricted mean prosthetic
dysfunction was 11.4 years for patients with biological prostheses and
19.4 years for mechanical prostheses. The Cox proportional hazards
analysis in post-AVR patients is shown in Table 4.
Prosthetic valve dysfunction is shown in Tables 5 and 6. Patients who
were implanted with locally manufactured bioprostheses (INC valve) did
not show differences in cytokine levels, echocardiographic parameters,
or prosthetic valve dysfunction than imported bioprostheses Table 7.
Figure 2 show survival of functionality and we included a Graphical
abstract